Peptide-Based Therapeutics for Oncology

Fisher, E. N.; Pavlenko, Kirill; Vlasov, Alexander M.; Ramenskaya, G. V.

doi:10.1007/s40290-018-0261-7

Cited by 25 publications

(19 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It will also require a large amount of the recombinant PrP-N, which is expensive to produce. It is possible to design synthetic modified short PrP-N peptides that have high stability and long half-life in vivo [65][66][67], but it will require a lot of experimentation to optimize and validate. Alternatively, fusion with a structured domain may stabilize the N1 peptide as suggested [64].…”

Section: Article Highlightsmentioning

confidence: 99%

Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development

Dexter

Kong

2021

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Introduction:The cellular prion protein (PrP C ), some of its derivatives (especially PrP N-terminal N1 peptide and shed PrP), and PrP C -containing exosomes have strong neuroprotective activities, which have been reviewed in the companion article (Part I) and are briefly summarized here. Areas covered: We propose that elevating the extracellular levels of a protective PrP form using gene therapy and other approaches is a very promising novel avenue for prophylactic and therapeutic treatments against prion disease, Alzheimer's disease, and several other neurodegenerative diseases. We will dissect the pros and cons of various potential PrP-based treatment options and propose a few strategies that are more likely to succeed. The cited references were obtained from extensive PubMed searches of recent literature, including peer-reviewed original articles and review articles. Expert opinion: Concurrent knockdown of celllular PrP expression and elevation of the extracellular levels of a neuroprotective PrP N-terminal peptide via optimized gene therapy vectors is a highly promising broad-spectrum prophylactic and therapeutic strategy against several neurodegenerative diseases, including prion diseases, Alzheimer's disease and Parkinson's disease.

show abstract

Section: Article Highlightsmentioning

confidence: 99%

Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development

Dexter

Kong

2021

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Short peptides have features of oligomers rather than polymers [ 5 ], but there is no clear consensus among scientists. In the literature, we can find contradictory information, with fewer than 30 [ 27 , 28 , 29 ] or 50 [ 30 , 31 , 32 , 33 ], up to 100 residues [ 34 ]. On the other hand, ultra-short peptides were precisely defined as peptides consisting of up to seven amino acids [ 35 , 36 , 37 , 38 ].…”

Section: Short Peptides: Definitionmentioning

confidence: 99%

A Global Review on Short Peptides: Frontiers and Perspectives

et al. 2021

View full text Add to dashboard Cite

Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed.

show abstract

“…ACPs can be also classified according to the strategy for obtaining peptides: (a) natural ACPs derived from the natural peptides of plants, animals, and humans; and (b) modified ACPs using recombinant technology and chemical synthesis ( Figure 1 C). Natural ACPs occur in nature in the form of fragmented proteins from plants, animals, and humans [ 72 ]. These peptides can act as potent agonists and antagonists for molecules associated with disease progression [ 73 ].…”

Section: Development Of Therapeutic Acpsmentioning

confidence: 99%

Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics

et al. 2022

View full text Add to dashboard Cite

Cancer is a group of diseases causing abnormal cell growth, altering the genome, and invading or spreading to other parts of the body. Among therapeutic peptide drugs, anticancer peptides (ACPs) have been considered to target and kill cancer cells because cancer cells have unique characteristics such as a high negative charge and abundance of microvilli in the cell membrane when compared to a normal cell. ACPs have several advantages, such as high specificity, cost-effectiveness, low immunogenicity, minimal toxicity, and high tolerance under normal physiological conditions. However, the development and identification of ACPs are time-consuming and expensive in traditional wet-lab-based approaches. Thus, the application of artificial intelligence on the approaches can save time and reduce the cost to identify candidate ACPs. Recently, machine learning (ML), deep learning (DL), and hybrid learning (ML combined DL) have emerged into the development of ACPs without experimental analysis, owing to advances in computer power and big data from the power system. Additionally, we suggest that combination therapy with classical approaches and ACPs might be one of the impactful approaches to increase the efficiency of cancer therapy.

show abstract

Peptide-Based Therapeutics for Oncology

Cited by 25 publications

References 124 publications

Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development

Neuroprotective effect and potential of cellular prion protein and its cleavage products for treatment of neurodegenerative disorders part II: strategies for therapeutics development

A Global Review on Short Peptides: Frontiers and Perspectives

Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics

Contact Info

Product

Resources

About